LUNGevity Foundation shared a post on LinkedIn:
“Clinical trial access for lung cancer patients should be expanding to new locations. But new research from LUNGevity’s Transforming Clinical Trials Initiative (TCTI) suggests clinical trials may be concentrating at large medical centers.
Why it matters: When trials are only available at a handful of hospitals, patients and caregivers have to travel long distances for cutting-edge treatment. However, extensive travel isn’t possible for many people because of cost, time off work, childcare responsibilities, and/or their health.
Now that LUNGevity has understood and documented the problem, we’re taking action to support people with lung cancer. Based on these findings, TCTI is working with FDA leaders, drug developers, clinicians, patient advocates and others to raise awareness and drive change.
If you’d like to learn about these findings and what LUNGevity is doing to address this issue, this article is for you.”
Lung Cancer Hope Month 2026: Celebrating Progress in Modern Oncology
